I've had a similar experience .
I spent over an hr in an Ophthalmologist office and while there I overheard his staff repeatedly calling his patients asking them to come in and have their Eylea eye shots redone .
Kodiak's KSI-301 has excellent safety and longer durability ..so far ...so Im sure his patients would prefer 1 eye shot every 6 mths than 1 every 2-3 mths .
Data from their pivotal trial will be out early next yr.
The sell off last yr was because they added another trial ....thus potentially delaying final data set for FDA approval ...and spending more cash on hand.
However the Baker Bros kept on buying ...now own close to 30% of the Co .
On another note ...SWAV has a huge data presentation set for TCT2021 ...later this week
Good luck
Kiwi
Recent KOD News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:00:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 08:39:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:11:00 PM
- Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences • PR Newswire (US) • 05/29/2024 08:36:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:10:18 PM
- Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results • PR Newswire (US) • 05/15/2024 08:01:00 PM
- Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy • PR Newswire (US) • 05/13/2024 11:32:00 PM
- Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform • PR Newswire (US) • 05/02/2024 08:30:00 PM
- Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results • PR Newswire (US) • 03/28/2024 10:30:00 AM
- Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024 • PR Newswire (US) • 03/26/2024 10:15:00 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:23:00 PM
- Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting • PR Newswire (US) • 01/30/2024 11:30:00 AM
- Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference • PR Newswire (US) • 01/04/2024 09:15:00 PM
- Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference • PR Newswire (US) • 11/21/2023 09:15:00 PM
- Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights • PR Newswire (US) • 11/14/2023 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 11:05:54 AM
- Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission • PR Newswire (US) • 11/06/2023 10:00:00 AM
- KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING • PR Newswire (US) • 11/02/2023 03:21:00 AM
- Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society • PR Newswire (US) • 10/11/2023 10:00:00 AM
- Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference • PR Newswire (US) • 09/08/2023 10:00:00 AM
- New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion • PR Newswire (US) • 09/07/2023 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/17/2023 09:26:42 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:33:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:12:57 PM
- Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights • PR Newswire (US) • 08/14/2023 08:01:00 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM